Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Centene

Zoetis

These are the health care stocks with the best value, fastest growth, and most momentum for January.

Top Health Care Stocks for January 2020

Biogen stock popped in mid-October after the biotech company said a broader analysis showed some promise for its Alzheimer's treatment, aducanumab. Is now the time to buy Biogen stock?

Is Biogen Stock A Buy On Renewed Hope In Alzheimer's Disease?

Gilead Sciences

Are these stocks value traps or bargain buys?

Better Buy:  Gilead Sciences  vs.  Biogen

Bristol-Myers

Drug manufacturers across the globe raised the list prices of more than 250 therapies on New Year’s Day, according to aggregate reports from Reuters and research firm 3 Axis Advisors.

Drugmakers Kick Off 2020 With Margin-Expanding Price Hikes

Pfizer

Happy New Year … hope you don’t need a prescription in 2020.

Big Pharma raises prescription drug prices on New Year’s Day

Drugmakers including Bristol-Myers Squibb, Gilead Sciences, and Biogen hiked U.S. list prices on more than 50 drugs on Wednesday.

Bristol-Myers, Gilead, and Biogen hike US drug prices as the new year begins

GlaxoSmithKline

Sanofi

Drugmakers including Bristol-Myers Squibb Co, Gilead Sciences Inc, and Biogen Inc hiked U.S. list prices on more than 50 drugs on Wednesday, bringing total New Year's Day drug price increases to more than 250, according to data analyzed by healthcare research firm 3 Axis Advisors.

More drugmakers hike U.S. prices as new year begins

Biogen: Buyback Signal

The FDA's call on whether to approve Biogen's experimental Alzheimer's drug, aducanumab, will be the "most important decision" it will make in 2020, Bernstein analyst Ronny Gal says.

This is 'the most important decision' the FDA will make in 2020, says analyst

Looking At Biogen For The Long Term

Alexion Pharma

Amgen

MannKind

The short interest data are out for the most recent settlement date, December 13. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Major Biotechs See Rising Short Interest

Applied Materials

Advantest Corp

Chipotle

Garmin

Lithia Motors

Mastercard

Microsoft

Synopsys

Target

My Stock Picks For 2020

Biogen sees its Relative Strength Rating hit the 80-plus level.
The post Stock Upgrades: Biogen Shows Rising Relative Strength appeared first on Investor's Business Daily.

Stock Upgrades: Biogen Shows Rising Relative Strength

Intel

iShares Russell 1000 Value ETF

JPMorgan Chase & Co

Phillips 66

Value stocks are hot these days, and the best part is the shift toward them isn't stopping anytime soon. Here are five to buy today.

Make the Shift Toward Value Stocks With These 5 Picks

Biogen's (BIIB) gosuranemab fails to meet primary endpoint in a phase II study evaluating gosuranemab (BIIB092) in patients with progressive supranuclear palsy, a degenerative brain disorder.

Biogen's Gosuranemab Fails in Phase II Brain Disorder Study

Despite rock-bottom valuation figures, Biogen may not be worth the risk.

Is Biogen Too Cheap to Ignore?

Biogen Inc. BIIB, +0.55% said Friday a trial of a treatment for a rare brain disorder called progressive supranuclear palsy missed its main goal and that it will discontinue its development.

Biogen to discontinue development of treatment for rare brain disorder after trial misses goals

The primary endpoint of the Phase 2 PASSPORT study was not met, and further development of gosuranemab in progressive supranuclear palsy (PSP) will not be pursued The primary endpoint of the Phase 2 PASSPORT study was not met, and further development of gosuranemab in progressive supranuclear palsy (PSP) will not be pursued

Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy

Following some confusing trial results last week, investors -- and regulators -- need more information.

Should Investors Be Worried About Biogen's Alzheimer's Drug?

Aducanumab Data A Positive For Biogen Regardless Of FDA Approval Timeline

Which stock wins in a battle between these two big biotechs?

Better Buy:  Biogen vs.  Amgen

"It's a complete coin flip that will now be in the hands of the FDA," says Jared Holz, a health-care strategist at Jefferies.

Biogen's potentially game-changing Alzheimer's drug still faces an uphill battle with the FDA

Biogen’s update on its investigative Alzheimer’s drug may not be the positive signal investors were hoping for.

Why Biogen’s Alzheimer’s Drug Presentation Left Investors Uninspired

Analysts offered split views of Biogen's controversial Alzheimer's treatment on Friday after the biotech company suggested a high dose of the drug works. Biogen stock rose midday Friday.

Will The FDA Approve Biogen's Controversial Alzheimer's Drug?

Questions Linger After CTAD For Biogen's Aducanumab, But Trading Opportunities Exist

News for Biogen Stock (BIIB)